Transcription termination and antitermination of bacterial CRISPR arrays

  1. Anne M Stringer
  2. Gabriele Baniulyte
  3. Erica Lasek-Nesselquist
  4. Kimberley D Seed
  5. Joseph T Wade  Is a corresponding author
  1. Wadsworth Center, New York State Department of Health, United States
  2. University of California, Berkeley, United States

Abstract

A hallmark of CRISPR-Cas immunity systems is the CRISPR array, a genomic locus consisting of short, repeated sequences ('repeats') interspersed with short, variable sequences ('spacers'). CRISPR arrays are transcribed and processed into individual CRISPR RNAs that each include a single spacer, and direct Cas proteins to complementary sequence in invading nucleic acid. Most bacterial CRISPR array transcripts are unusually long for untranslated RNA, suggesting the existence of mechanisms to prevent premature transcription termination by Rho, a conserved bacterial transcription termination factor that rapidly terminates untranslated RNA. We show that Rho can prematurely terminate transcription of bacterial CRISPR arrays, and we identify a widespread antitermination mechanism that antagonizes Rho to facilitate complete transcription of CRISPR arrays. Thus, our data highlight the importance of transcription termination and antitermination in the evolution of bacterial CRISPR-Cas systems.

Data availability

Raw ChIP-seq data are available from EBI ArrayExpress/ENA using accession number E-MTAB-7242. Raw sequencing data for conjugation experiments involving V. cholerae are available from EBI ArrayExpress/ENA using accession number E-MTAB-9631.

The following data sets were generated

Article and author information

Author details

  1. Anne M Stringer

    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Gabriele Baniulyte

    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0235-7938
  3. Erica Lasek-Nesselquist

    Bioinformatics Core Facility, Wadsworth Center, New York State Department of Health, Albany, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Kimberley D Seed

    Department of Plant & Microbial Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0139-1600
  5. Joseph T Wade

    Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, United States
    For correspondence
    joseph.wade@gmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9779-3160

Funding

National Institute of General Medical Sciences (R01GM122836)

  • Joseph T Wade

National Institute of Allergy and Infectious Diseases (R21AI126416)

  • Joseph T Wade

National Institute of Allergy and Infectious Diseases (R01AI127652)

  • Kimberley D Seed

Burroughs Wellcome Fund (Investigators in the Pathogenesis of Infectious Disease Award)

  • Kimberley D Seed

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Stringer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anne M Stringer
  2. Gabriele Baniulyte
  3. Erica Lasek-Nesselquist
  4. Kimberley D Seed
  5. Joseph T Wade
(2020)
Transcription termination and antitermination of bacterial CRISPR arrays
eLife 9:e58182.
https://doi.org/10.7554/eLife.58182

Share this article

https://doi.org/10.7554/eLife.58182

Further reading

    1. Genetics and Genomics
    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics
    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.